Limits...
Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.

Zarogouldis P, Karamanos NK, Porpodis K, Domvri K, Huang H, Hohenforst-Schimdt W, Goldberg EP, Zarogoulidis K - Int J Mol Sci (2012)

Bottom Line: Inhaled gene therapy has presented safety and effectiveness previously in cystic fibrosis.During the last decade, numerous new nanocomplexes have been created and investigated as a safe gene delivery nano-vehicle.These formulations are multifunctional; they can be used as either local therapy or carrier for an effective inhaled gene therapy for lung cancer.

View Article: PubMed Central - PubMed

Affiliation: Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece; E-Mails: kporpodis@yahoo.gr (K.P.); kellybio4@hotmail.com (K.D.); zarog@med.auth.gr (K.Z.) ; Pulmonary Department-Interventional Unit, "Ruhrland Klinik", University of Essen, Essen 45239, Germany.

ABSTRACT
Novel aerosol therapeutic modalities have been investigated for lung cancer. Inhaled gene therapy has presented safety and effectiveness previously in cystic fibrosis. However, safety concerns have been raised regarding the safety of non-viral vectors for inhaled gene therapy in lung cancer, and therefore small steps have been made towards this multifunctional treatment modality. During the last decade, numerous new nanocomplexes have been created and investigated as a safe gene delivery nano-vehicle. These formulations are multifunctional; they can be used as either local therapy or carrier for an effective inhaled gene therapy for lung cancer. Herein, we present current and future perspectives of nanocomplexes for inhaled gene therapy treatment in lung cancer.

No MeSH data available.


Related in: MedlinePlus

Aerosol gene therapy modality parameters; (A) formulation and lung microenvironment; (B) current and future vector systems. Figure by Paul Zarogoulidis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3472716&req=5

f2-ijms-13-10828: Aerosol gene therapy modality parameters; (A) formulation and lung microenvironment; (B) current and future vector systems. Figure by Paul Zarogoulidis.

Mentions: It should be clarified that the reason we need local aerosol therapy for lung cancer is to deliver a smaller amount of therapeutic agent and therefore have less systemic side effects. In addition, micro-metastasis will be controlled either locally in the lung parenchyma, or in other organs through the vascular and lymphatic circulation of the chemotherapeutic agent [19]. Another aspect that should be incorporated in this section is the modification of the respiratory properties. It has been shown that the addition of 5%–7% CO2 through the nebulization process (aerosol gene therapy) can decrease the respiratory rate and increase the tidal volume by 150% (deep breathing pattern) [60–64]. Nevertheless, a higher concentration can lead to dizziness and sleepiness [65]. Another option would be the nebulization of a drug formulation in heliox. This low-density gas mixture has the ability to reduce flow resistance, in consequence allowing more aerosol to be deposited in the alveoli region (Figure 2) [66]. The CO2 has been co-administered in nebulized inhaled chemotherapy trials and inhaled gene therapy trials.


Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.

Zarogouldis P, Karamanos NK, Porpodis K, Domvri K, Huang H, Hohenforst-Schimdt W, Goldberg EP, Zarogoulidis K - Int J Mol Sci (2012)

Aerosol gene therapy modality parameters; (A) formulation and lung microenvironment; (B) current and future vector systems. Figure by Paul Zarogoulidis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3472716&req=5

f2-ijms-13-10828: Aerosol gene therapy modality parameters; (A) formulation and lung microenvironment; (B) current and future vector systems. Figure by Paul Zarogoulidis.
Mentions: It should be clarified that the reason we need local aerosol therapy for lung cancer is to deliver a smaller amount of therapeutic agent and therefore have less systemic side effects. In addition, micro-metastasis will be controlled either locally in the lung parenchyma, or in other organs through the vascular and lymphatic circulation of the chemotherapeutic agent [19]. Another aspect that should be incorporated in this section is the modification of the respiratory properties. It has been shown that the addition of 5%–7% CO2 through the nebulization process (aerosol gene therapy) can decrease the respiratory rate and increase the tidal volume by 150% (deep breathing pattern) [60–64]. Nevertheless, a higher concentration can lead to dizziness and sleepiness [65]. Another option would be the nebulization of a drug formulation in heliox. This low-density gas mixture has the ability to reduce flow resistance, in consequence allowing more aerosol to be deposited in the alveoli region (Figure 2) [66]. The CO2 has been co-administered in nebulized inhaled chemotherapy trials and inhaled gene therapy trials.

Bottom Line: Inhaled gene therapy has presented safety and effectiveness previously in cystic fibrosis.During the last decade, numerous new nanocomplexes have been created and investigated as a safe gene delivery nano-vehicle.These formulations are multifunctional; they can be used as either local therapy or carrier for an effective inhaled gene therapy for lung cancer.

View Article: PubMed Central - PubMed

Affiliation: Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece; E-Mails: kporpodis@yahoo.gr (K.P.); kellybio4@hotmail.com (K.D.); zarog@med.auth.gr (K.Z.) ; Pulmonary Department-Interventional Unit, "Ruhrland Klinik", University of Essen, Essen 45239, Germany.

ABSTRACT
Novel aerosol therapeutic modalities have been investigated for lung cancer. Inhaled gene therapy has presented safety and effectiveness previously in cystic fibrosis. However, safety concerns have been raised regarding the safety of non-viral vectors for inhaled gene therapy in lung cancer, and therefore small steps have been made towards this multifunctional treatment modality. During the last decade, numerous new nanocomplexes have been created and investigated as a safe gene delivery nano-vehicle. These formulations are multifunctional; they can be used as either local therapy or carrier for an effective inhaled gene therapy for lung cancer. Herein, we present current and future perspectives of nanocomplexes for inhaled gene therapy treatment in lung cancer.

No MeSH data available.


Related in: MedlinePlus